TSHA
NASDAQTaysha Gene Therapies Inc.
Website
News25/Ratings12
News · 26 weeks390%
2025-10-262026-04-19
Mix2490d
- SEC Filings12(50%)
- Insider5(21%)
- Other5(21%)
- Earnings2(8%)
Latest news
25 items- SECSEC Form DEFA14A filed by Taysha Gene Therapies Inc.DEFA14A - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- SECSEC Form DEF 14A filed by Taysha Gene Therapies Inc.DEF 14A - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- INSIDERSEC Form 4 filed by Nagendran Sukumar4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- PRTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies,
- SECSEC Form 10-K filed by Taysha Gene Therapies Inc.10-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- SECTaysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
- PRTaysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate UpdateDosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ
- PRTaysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on
- PRTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company's common stock and an option to purchase 134,460 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Alam Kamran sold $7,481 worth of shares (1,655 units at $4.52), decreasing direct ownership by 0.11% to 1,442,131 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- PRTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering empl
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- INSIDERPresident and Head of R&D Nagendran Sukumar sold $547,469 worth of shares (116,050 units at $4.72), decreasing direct ownership by 8% to 1,317,389 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- INSIDERChief Executive Officer Nolan Sean P. sold $840,196 worth of shares (178,101 units at $4.72), decreasing direct ownership by 6% to 2,908,257 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Alam Kamran sold $485,042 worth of shares (102,817 units at $4.72), decreasing direct ownership by 7% to 1,443,786 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- SECSEC Form 144 filed by Taysha Gene Therapies Inc.144 - Taysha Gene Therapies, Inc. (0001806310) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Alam Kamran was granted 359,000 shares, increasing direct ownership by 30% to 1,546,603 units (SEC Form 4)4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)